SK286719B6 - Použitie derivátov kyseliny fumarovej na liečenie mitochondriálnych chorôb - Google Patents

Použitie derivátov kyseliny fumarovej na liečenie mitochondriálnych chorôb Download PDF

Info

Publication number
SK286719B6
SK286719B6 SK652-2002A SK6522002A SK286719B6 SK 286719 B6 SK286719 B6 SK 286719B6 SK 6522002 A SK6522002 A SK 6522002A SK 286719 B6 SK286719 B6 SK 286719B6
Authority
SK
Slovakia
Prior art keywords
fumarate
fumaric acid
methyl
ethyl
use according
Prior art date
Application number
SK652-2002A
Other languages
English (en)
Slovak (sk)
Other versions
SK6522002A3 (en
Inventor
Rajendra Kumar Joshi
Hans-Peter Strebel
Original Assignee
Fumapharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fumapharm Ag filed Critical Fumapharm Ag
Publication of SK6522002A3 publication Critical patent/SK6522002A3/sk
Publication of SK286719B6 publication Critical patent/SK286719B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
SK652-2002A 2000-01-10 2000-12-11 Použitie derivátov kyseliny fumarovej na liečenie mitochondriálnych chorôb SK286719B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10000577A DE10000577A1 (de) 2000-01-10 2000-01-10 Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
PCT/EP2000/012504 WO2001051047A1 (de) 2000-01-10 2000-12-11 Verwendung von fumarsäurederivaten zur behandlung mitochondrialer krankheiten

Publications (2)

Publication Number Publication Date
SK6522002A3 SK6522002A3 (en) 2002-11-06
SK286719B6 true SK286719B6 (sk) 2009-04-06

Family

ID=7627026

Family Applications (1)

Application Number Title Priority Date Filing Date
SK652-2002A SK286719B6 (sk) 2000-01-10 2000-12-11 Použitie derivátov kyseliny fumarovej na liečenie mitochondriálnych chorôb

Country Status (28)

Country Link
US (1) US6858750B2 (sh)
EP (1) EP1248606B1 (sh)
JP (1) JP2003529556A (sh)
CN (1) CN1433303A (sh)
AT (1) ATE329590T1 (sh)
AU (1) AU772409B2 (sh)
BG (1) BG65468B1 (sh)
BR (1) BR0016935A (sh)
CA (1) CA2390886C (sh)
CY (1) CY1105462T1 (sh)
CZ (1) CZ303680B6 (sh)
DE (2) DE10000577A1 (sh)
DK (1) DK1248606T3 (sh)
EE (1) EE05051B1 (sh)
ES (1) ES2265367T3 (sh)
HU (1) HU229138B1 (sh)
IL (2) IL150516A0 (sh)
MX (1) MXPA02006695A (sh)
NO (1) NO326875B1 (sh)
NZ (1) NZ518781A (sh)
PL (1) PL223342B1 (sh)
PT (1) PT1248606E (sh)
RS (1) RS50185B (sh)
RU (1) RU2218918C1 (sh)
SI (1) SI1248606T1 (sh)
SK (1) SK286719B6 (sh)
WO (1) WO2001051047A1 (sh)
ZA (1) ZA200205481B (sh)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
JP2004523511A (ja) * 2001-01-12 2004-08-05 フーマファーム アーゲー フマル酸アミド類
DE10217314A1 (de) * 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
US7224426B2 (en) * 2002-07-31 2007-05-29 Dai Nippon Printing Co., Ltd. Optical element
BRPI0410805A (pt) * 2003-09-09 2006-06-27 Fumapharm Ag uso de derivados do ácido fumárico para tratamento da insuficiência cardìaca e asma
DE14172398T1 (de) * 2004-10-08 2015-01-08 Forward Pharma A/S Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester
EP1915387B1 (en) * 2005-07-07 2010-01-20 Aditech Pharma AG Novel glucopyranose esters and glucofuranose esters of alkyl- fumarates and their pharmaceutical use
US20080227847A1 (en) * 2005-07-07 2008-09-18 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
AU2007328210B2 (en) * 2006-12-06 2012-11-22 Cornell Research Foundation, Inc. Intermediate duration neuromuscular blocking agents and antagonists thereof
HRP20220902T3 (hr) 2007-02-08 2022-10-14 Biogen Ma Inc. Pripravci i njihova upotreba u liječenju multiple skleroze
EP3135282A1 (en) * 2007-02-08 2017-03-01 Biogen MA Inc. Neuroprotection in demyelinating diseases
DK2334378T3 (da) 2008-08-19 2014-07-07 Xenoport Inc Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse
PT2564839T (pt) * 2009-01-09 2016-07-14 Forward Pharma As Formulação farmacêutica compreendendo um ou mais ésteres de ácido fumárico numa matriz de erosão
WO2010079221A1 (en) * 2009-01-09 2010-07-15 Forward Pharma A/S Pharmaceutical composition comprising one or more fumaric acid esters
WO2010107488A1 (en) 2009-03-17 2010-09-23 Cornell University Reversible nondepolarizing neuromuscular blockade agents and methods for their use
WO2011022491A1 (en) 2009-08-19 2011-02-24 Cornell University Cysteine for physiological injection
CA2865316A1 (en) * 2011-04-28 2012-11-01 Gino Cortopassi Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
HUE036085T2 (hu) 2011-06-08 2018-06-28 Biogen Ma Inc Nagy tisztaságú és kristályos dimetil-fumarát elõállítására szolgáló eljárás
EP2782561A1 (en) 2011-11-24 2014-10-01 Synthon BV Controlled release particles comprising dimethyl fumarate
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
MX2014009511A (es) 2012-02-07 2014-10-24 Xenoport Inc Compuestos de fumarato de morfolinoalquilo, composiciones farmaceuticas y metodos de uso.
CN114146079A (zh) 2012-02-07 2022-03-08 比奥根玛公司 含有富马酸二甲酯的药物组合物
AU2013305684B2 (en) 2012-08-22 2016-11-24 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US20140179779A1 (en) 2012-12-21 2014-06-26 Biogen Idec Ma Inc. Deuterium Substituted Fumarate Derivatives
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
HUE040044T2 (hu) 2013-03-14 2019-02-28 Alkermes Pharma Ireland Ltd Fumarátok prodrugjai, és azok alkalmazása különbözõ betegségek kezelésében
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en) 2013-06-07 2016-04-05 Xenoport, Inc. Method of making monomethyl fumarate
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
TW201516020A (zh) 2013-09-06 2015-05-01 Xenoport Inc （ｎ，ｎ－二乙基胺甲醯基）甲基（２ｅ）丁－２－烯－１，４－二酸甲酯之晶形、合成方法及用途
US9604922B2 (en) 2014-02-24 2017-03-28 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2016061393A1 (en) 2014-10-15 2016-04-21 Xenoport, Inc. Fumarate compounds, pharmaceutical compositions, and methods of use
SG11201705124QA (en) 2015-02-08 2017-07-28 Alkermes Pharma Ireland Ltd Monomethylfumarate prodrug compositions
ES2826825T3 (es) 2015-03-27 2021-05-19 Symbionyx Pharmaceuticals Inc Composiciones y métodos para el tratamiento de la psoriasis
AU2016273068A1 (en) 2015-06-01 2017-12-21 Sun Pharmaceutical Industries Ltd. Pharmaceutical compositions of dimethyl fumarate
WO2017060400A1 (en) 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions
IT201700087359A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
IT201700087376A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
RU2674286C1 (ru) * 2018-03-20 2018-12-07 Исмагилов Искандар Халиуллович Средство для лечения заболевания, обусловленного нарушением окислительного стресса
RU2742745C1 (ru) * 2019-09-24 2021-02-10 Акционерное общество "Исследовательский Институт Химического Разнообразия" Лекарственная форма в виде капсулы, содержащая таблетки с диметилфурмаратом

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530372A1 (de) * 1975-07-08 1977-01-13 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
DE2621214C3 (de) * 1976-05-13 1981-11-12 Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen
CH664150A5 (de) * 1985-01-15 1988-02-15 Peter Paul Prof Dr Speiser Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
JPS61194020A (ja) * 1985-02-22 1986-08-28 Dai Ichi Seiyaku Co Ltd 網膜症治療剤
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
IT1251166B (it) * 1991-08-09 1995-05-04 Chiesi Farma Spa Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono
JPH09510222A (ja) * 1994-03-16 1997-10-14 ノボ ノルディスク アクティーゼルスカブ ２，３，４，５−テトラヒドロ−１ｈ−３−ベンゾアゼピン化合物の酸付加塩
DE19721099C2 (de) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
EP1032403B1 (en) * 1997-10-24 2012-05-02 John P. Blass Nutritional supplement for cerebral metabolic insufficiencies
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
US6812248B2 (en) * 2000-07-05 2004-11-02 John Hopkins University School Of Medicine Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes

Also Published As

Publication number Publication date
DE50013000D1 (de) 2006-07-27
CZ20021522A3 (cs) 2002-10-16
CZ303680B6 (cs) 2013-02-27
MXPA02006695A (es) 2002-10-23
CA2390886A1 (en) 2001-07-19
SI1248606T1 (sl) 2006-10-31
EP1248606A1 (de) 2002-10-16
ES2265367T3 (es) 2007-02-16
HUP0204182A3 (en) 2003-05-28
BG65468B1 (bg) 2008-09-30
IL150516A0 (en) 2003-02-12
US6858750B2 (en) 2005-02-22
ATE329590T1 (de) 2006-07-15
CY1105462T1 (el) 2010-04-28
WO2001051047A1 (de) 2001-07-19
HU229138B1 (en) 2013-08-28
YU51402A (sh) 2006-01-16
CN1433303A (zh) 2003-07-30
PT1248606E (pt) 2006-08-31
HUP0204182A2 (hu) 2003-04-28
EE05051B1 (et) 2008-08-15
EP1248606B1 (de) 2006-06-14
AU772409B2 (en) 2004-04-29
JP2003529556A (ja) 2003-10-07
PL356714A1 (en) 2004-06-28
NO20022175D0 (no) 2002-05-07
PL223342B1 (pl) 2016-10-31
SK6522002A3 (en) 2002-11-06
BR0016935A (pt) 2003-04-01
RS50185B (sr) 2009-05-06
NO326875B1 (no) 2009-03-09
BG106685A (en) 2003-01-31
WO2001051047A8 (de) 2001-08-16
ZA200205481B (en) 2004-01-28
EE200200333A (et) 2003-08-15
DK1248606T3 (da) 2006-08-21
NO20022175L (no) 2002-05-07
US20030013761A1 (en) 2003-01-16
IL150516A (en) 2009-02-11
RU2218918C1 (ru) 2003-12-20
DE10000577A1 (de) 2001-07-26
AU3156601A (en) 2001-07-24
CA2390886C (en) 2008-08-19
NZ518781A (en) 2004-04-30

Similar Documents

Publication Publication Date Title
SK286719B6 (sk) Použitie derivátov kyseliny fumarovej na liečenie mitochondriálnych chorôb
JP3553883B2 (ja) フマル酸誘導体を含有する移植医療における治療剤
SK41599A3 (en) Use of fumaric acid derivatives
WO2002055066A1 (de) Fumarsäurederivate als nf-kappab-inhibitor
EP2167098B1 (en) Allopregnanolone in a method for enhancing neurological function (alzheimer disease)
EP1233758B1 (de) Natriumvalproat-granulat mit verringerter hygroskopizität
JPH10259126A (ja) アルツハイマー病治療・予防剤
EP0952826A1 (en) Idebenone containing combination agent for treating alzheimer&#39;s disease
WO2004056306A2 (de) Verwendung von l-dopa, seiner derivate und diese verbindungen enthaltender arzneimittel zur prophylaxe psychotischer erkrankungen
US20110224300A1 (en) USE OF POTASSIUM 2-(a- HYDROXYPENTYL) BENZOATE IN THE MANUFACTURE OF MEDICAMENTS FOR PREVENTING AND/OR TREATING SENILE DEMENTIA
WO2015105064A1 (ja) 網膜疾患の予防又は治療のための医薬組成物
MXPA01002031A (es) El uso de derivados de acido fumarico en la medicina de transplante

Legal Events

Date Code Title Description
TC4A Change of owner's name

Owner name: BIOGEN IDEC INTERNATIONAL GMBH, ZUG, CH

Effective date: 20140623

TC4A Change of owner's name

Owner name: BIOGEN INTERNATIONAL GMBH, ZUG, CH

Effective date: 20170622

MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20161211